N/A
Completed N=1,226
This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.
Arthritis Rheumatoid
Source: ClinicalTrials.gov NCT04267614 ↗
Enrolled (actual)
1,226
Serious AEs
—
Results posted
Jul 2023
Primary outcomePrimary: Disease Activity Score 28 (DAS28) at Month 12 — 4.56; 4.9 Units on a scale — p=<0.05
Summary
This study is to investigate the effect of etanercept in early versus delayed referral for management of rheumatoid arthritis patients assessing real-world patient data entered in the Iraq National Center of Rheumatology database between May 2012 and May 2017.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Disease Activity Score 28 (DAS28) at Month 12 |
4.56; 4.9 | <0.05 sig |
| PRIMARY Clinical Disease Activity Index (CDAI) Score at Month 12 |
19; 22 | <0.05 sig |
Eligibility Criteria
Inclusion Criteria
- Diagnosed RA patients.
- 18 years old and above.
- Did not receive pervious biological treatment.
Exclusion Criteria
- Had previous biological treatment
- Use etanercept for less than 1 year
Data sourced from ClinicalTrials.gov (NCT04267614). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.